Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease

被引:220
作者
Collins, S. J.
Sanchez-Juan, P.
Masters, C. L.
Klug, G. M.
van Duijn, C.
Poleggi, A.
Pocchiari, M.
Almonti, S.
Cuadrado-Corrales, N.
de Pedro-Cuesta, J.
Budka, H.
Gelpi, E.
Glatzel, M.
Tolnay, M.
Hewer, E.
Zerr, I.
Heinemann, U.
Kretszchmar, H. A.
Jansen, G. H.
Olsen, E.
Mitrova, E.
Alperovitch, A.
Brandel, J. -P.
Mackenzie, J.
Murray, K.
Will, R. G.
机构
[1] Univ Melbourne, Australian Natl Creutzfeldt Jakob Dis Registry, Dept Pathol, Parkville, Vic 3052, Australia
[2] Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands
[3] Ist Super Sanita, Natl Registry Creutzfeldt Jakob Dis, Dept Cell Biol & Neurosci, I-00161 Rome, Italy
[4] Inst Salud Carlos III, Natl HTSE Lab Unit, Ctr Microbiol, Madrid, Spain
[5] Inst Salud Carlos III, Natl HTSE Registry, Ctr Epidemiol, Madrid, Spain
[6] Med Univ Vienna, Austrian Reference Ctr Human Prion Dis, Inst Neurol, Vienna, Austria
[7] Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland
[8] Univ Zurich Hosp, Natl Reference Ctr Prion Dis, CH-8091 Zurich, Switzerland
[9] Univ Gottingen, Dept Neurol, D-3400 Gottingen, Germany
[10] Univ Munich, Dept Neuropathol, Munich, Germany
[11] Publ Hlth Agcy Canada, Ctr Infect Dis Prevent & Control, Ottawa, ON, Canada
[12] Slovak Med Univ, Inst Prevent & Clin Med, Res Base, Bratislava, Slovakia
[13] Hop La Pitie Salpetriere, U708, INSERM, Paris, France
[14] Western Gen Hosp, Natl CJD Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland
关键词
sporadic CJD; diagnostic investigation results; molecular sub-typing;
D O I
10.1093/brain/awl159
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To validate the provisional findings of a number of smaller studies and explore additional determinants of characteristic diagnostic investigation results across the entire clinical spectrum of sporadic Creutzfeldt-Jakob disease (CJD), an international collaborative study was undertaken comprising 2451 pathologically confirmed (definite) patients. We assessed the influence of age at disease onset, illness duration, prion protein gene (PRNP) codon 129 polymorphism (either methionine or valine) and molecular sub-type on the diagnostic sensitivity of EEG, cerebral MR1 and the CSIF 14-3-3 immunoassay. For EEG and CSF 14-3-3 protein detection, we also assessed the influence of the time point in a patient's illness at which the investigation was performed on the likelihood of a typical or positive result. Analysis included a large subset of patients (n = 743) in whom molecular sub-typing had been performed using a combination of the PRNP codon 129 polymorphism and the form of protease resistant prion protein [type 1 or 2 according to Parchi et al. (Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichemberger N, Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar H. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neural 1999; 46: 224-233.)] present in the brain. Findings for the whole group paralleled the subset with molecular sub-typing data available, showing that age at disease onset and disease duration were independent determinants of typical changes on EEG, while illness duration significantly influenced positive CSF 14-3-3 protein detection; changes on brain MRI were not influenced by either of these clinical parameters, but overall, imaging data were less complete and consequently conclusions are more tentative. In addition to age at disease onset and illness duration, molecular sub-type was re-affirmed as an important independent determinant of investigation results. In multivariate analyses that included molecular sub-type, time point of the investigation during a patient's illness was found not to influence the occurrence of a typical or positive EEG or CSF 14-3-3 protein result. A typical EEG was most often seen in MM I patients and was significantly less likely in the MV1, MV2 and VV2 sub-types, whereas VV2 patients had an increased likelihood of a typical brain MRI. Overall, the CSF 14-3-3 immunoassay was the most frequently positive investigation (88.1%) but performed significantly less well in the very uncommon MV2 and MM2 subtypes. Our findings confirm a number of determinants of principal investigation results in sporadic CJD and underscore the importance of recognizing these pre-test limitations before accepting the diagnosis excluded or confirmed. Combinations of investigations offer the best chance of detection, especially for the less common molecular sub-types such as MV2 and MM2.
引用
收藏
页码:2278 / 2287
页数:10
相关论文
共 24 条
[1]   Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease [J].
Castellani, RJ ;
Colucci, M ;
Xie, Z ;
Zou, W ;
Li, C ;
Parchi, P ;
Capellari, S ;
Pastore, M ;
Rahbar, MH ;
Chen, SG ;
Gambetti, P .
NEUROLOGY, 2004, 63 (03) :436-442
[2]   MRI of Creutzfeldt-Jakob disease: Imaging features and recommended MRI protocol [J].
Collie, DA ;
Sellar, RJ ;
Zeidler, M ;
Colchester, ACF ;
Knight, R ;
Will, RG .
CLINICAL RADIOLOGY, 2001, 56 (09) :726-739
[3]   Novel prion protein gene mutation in an octogenarian with Creutzfeldt-Jakob disease [J].
Collins, S ;
Boyd, A ;
Fletcher, A ;
Byron, K ;
Harper, C ;
McLean, CA ;
Masters, CL .
ARCHIVES OF NEUROLOGY, 2000, 57 (07) :1058-1063
[4]   Transmissible spongiform encephalopathies [J].
Collins, SJ ;
Lawson, VA ;
Masters, CL .
LANCET, 2004, 363 (9402) :51-61
[5]   MR imaging of Creutzfeldt-Jakob disease [J].
Finkenstaedt, M ;
Szudra, A ;
Zerr, I ;
Poser, S ;
Hise, JH ;
Stoebner, JM ;
Weber, T .
RADIOLOGY, 1996, 199 (03) :793-798
[6]   Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991-2002 [J].
Head, MW ;
Bunn, TJR ;
Bishop, MT ;
McLoughlin, V ;
Lowrie, S ;
McKimmie, CS ;
Williams, MC ;
McCardle, L ;
MacKenzie, J ;
Knight, R ;
Will, RG ;
Ironside, JW .
ANNALS OF NEUROLOGY, 2004, 55 (06) :851-859
[7]   Molecular classification of sporadic Creutzfeldt-Jakob disease [J].
Hill, AF ;
Joiner, S ;
Wadsworth, JDF ;
Sidle, KCL ;
Bell, JE ;
Budka, H ;
Ironside, JW ;
Collinge, J .
BRAIN, 2003, 126 :1333-1346
[8]   Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene [J].
Korth, C ;
Kaneko, K ;
Groth, D ;
Heye, N ;
Telling, G ;
Mastrianni, J ;
Parchi, P ;
Gambetti, P ;
Will, R ;
Ironside, J ;
Heinrich, C ;
Tremblay, P ;
DeArmond, SJ ;
Prusiner, SB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (08) :4784-4789
[9]   High incidence of genetic human transmissible spongiform encephalopathies in Italy [J].
Ladogana, A ;
Puopolo, M ;
Poleggi, A ;
Almonti, S ;
Mellina, V ;
Equestre, M ;
Pocchiari, M .
NEUROLOGY, 2005, 64 (09) :1592-1597
[10]   Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada [J].
Ladogana, A ;
Puopolo, M ;
Croes, EA ;
Budka, H ;
Jarius, C ;
Collins, S ;
Klug, GM ;
Sutcliffe, T ;
Giulivi, A ;
Alperovitch, A ;
Delasnerie-Laupretre, N ;
Brandel, JP ;
Poser, S ;
Kretzschmar, H ;
Rietveld, I ;
Mitrova, E ;
Cuesta, JD ;
Martinez-Martin, P ;
Glatzel, M ;
Aguzzi, A ;
Knight, R ;
Ward, H ;
Pocchiari, M ;
van Duijn, CM ;
Will, RG ;
Zerr, I .
NEUROLOGY, 2005, 64 (09) :1586-1591